Skip to content
value.today

Cartesian Therapeutics, Inc.

RNAC
$192 Mmarket cap on Oct 27, 2026+36.8% since Jan 2024
Compare
World rank
#16,359
Revenue
—
For year ending December-2025
Net income
$-130 M
SEC filing
Employees
58
As on 2021
value.today research

Cartesian Therapeutics, Inc. in brief

Cartesian Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Massachusetts, USA. It was founded in 2007. Its market value was $192 M on 27 October 2026, which makes it the 16,359th largest listed company in the world and the 3,167th largest in the USA on this site. It employs about 58 people. Its largest business segments by sales in 2025 were Operating (100%). Its shares trade under the symbol RNAC (Nasdaq).

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About Cartesian Therapeutics, Inc.

Selecta Biosciences is a Biopharmaceutical and Gene Therapy company wholly owned, proprietary pipeline and work with partners with the goal of addressing immunogenicity to create life changing therapies for patients and their families. The company annual revenue is 27.6 million USD and 39 employees as on 2019. The headquarters is in USA.

Cartesian Therapeutics, Inc. timeline

5 events, 2007–2023
  1. 2007
  2. 🏁
    · approximate
    Founded
  3. 2009
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2016
  6. 🔔
    · approximate
    Initial public offering on Nasdaq
  7. 2022
  8. 💰
    Record revenue of $111 million
    FY2022, the highest of the 7 years on record.
  9. 2023
  10. ✎
    Renamed Cartesian Therapeutics, Inc.
    Formerly Selecta Biosciences Inc.

Events of Cartesian Therapeutics, Inc. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$92 M$183 M$275 M$366 M2020202120222023202420252026

World rank over time

▼ down 750 places since 2020
2020-01-01: #15705#15,70520202021-01-01: #13303#13,30320212022-01-07: #15851#15,85120222022-12-25: #19583#19,58320222023-07-30: #19119#19,11920232024-01-05: #19732#19,73220242026-10-08: #16277#16,27720262026-10-27: #16455#16,4552026

Rank in USA: #3,209 (Jan 2020) · #2,890 (Jan 2021) · #3,336 (Jan 2022) · #3,948 (Dec 2022) · #3,780 (Jul 2023) · #3,482 (Jan 2024) · #3,122 (Oct 2026) · #3,184 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
-41.4%
Net margin
—
Operating margin
—
Return on equity
—
Liabilities / assets
142.6%
Net debt
$-125M
Revenue growth
+49.7%
R&D / revenue
115.9%
Profit per employee
$-2.2 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $1M, net income $-65M$1MFY18Fiscal year ending Dec 2019: revenue $7M, net income $-55M$7MFY19Fiscal year ending Dec 2020: revenue $17M, net income $-69M$17MFY20Fiscal year ending Dec 2021: revenue $85M, net income $-26M$85MFY21Fiscal year ending Dec 2022: revenue $111M, net income $35M$111MFY22Fiscal year ending Dec 2023: revenue $26M, net income $-220M$26MFY23Fiscal year ending Dec 2024: revenue $39M, net income $-77M$39MFY24Fiscal year ending Dec 2025: revenue —, net income $-130M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-143M$-130M—
Dec 2024$39M+49.7%$-44M$-77M-199.0%
Dec 2023$26M-76.5%$-86M$-220M-845.0%
Dec 2022$111M+30.2%$15M$35M31.9%
Dec 2021$85M+412.5%$-5M$-26M-30.2%
Dec 2020$17M+148.5%$-57M$-69M-414.9%
Dec 2019$7M+642.2%$-52M$-55M-828.6%
Dec 2018$1M—$-65M$-65M-7260.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-74M$5M$-79M$-5.02—
Dec 2024$-24M$9M$-33M$-4.49—
Dec 2023$-51M$0M$-51M$-49.76—
Dec 2022$-32M$1M$-33M$0.10—
Dec 2021$-60M$1M$-61M$-0.22—
Dec 2020$35M$1M$34M$-0.68—
Dec 2019$-51M$0M$-51M$-1.22—
Dec 2018$-59M$1M$-60M$-2.92—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-10M—Dec ’24Three months to Mar 2025: revenue $1M, net income $-18M$1MMar ’25Three months to Jun 2025: revenue $0M, net income $16M$0MJun ’25Three months to Sep 2025: revenue $0M, net income $-36M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-93M—Dec ’25Three months to Mar 2026: revenue $0M, net income $-39M$0MMar ’26Three months to Jun 2026: revenue —, net income $16M—Jun ’26Three months to Sep 2026: revenue —, net income $-11M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-11M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Cartesian Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-143 M
Net income
$-130 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$296 M
Total liabilities
$423 M
Total equity
$-126 M

As of December-2025

Top 100 institutional investors in Cartesian Therapeutics, Inc.#

As of Sep 30, 2026
100 institutions held 8.7 M shares (about 28.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 20.5%. Filings read through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Cartesian Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Squarepoint Ops LLC2,263,230+8,611 (+0.38%)7.42%$16 MNov 9, 2026
2BlackRock, Inc.808,458-10,781 (-1.32%)2.65%$6 MNov 13, 2026
3683 Capital Management, LLC751,000+101,000 (+15.54%)2.46%$5 MNov 16, 2026
4Vanguard Capital Management LLC555,8230 (0.00%)1.82%$4 MNov 13, 2026
5FMR LLC370,457+2,028 (+0.55%)1.21%$3 MNov 10, 2026
6Two Sigma Investments, LP367,350+71,057 (+23.98%)1.20%$3 MNov 16, 2026
7Geode Capital Management, LLC342,829-13,696 (-3.84%)1.12%$2 MNov 6, 2026
8AQR Capital Management LLC287,156-69,300 (-19.44%)0.94%$2 MNov 16, 2026
9State Street Corp261,736+12,524 (+5.03%)0.86%$2 MNov 12, 2026
10Marshall Wace, LLP243,545+10,626 (+4.56%)0.80%$2 MNov 13, 2026
11Millennium Management LLC221,858-88,029 (-28.41%)0.73%$2 MNov 16, 2026
12UBS Group AG207,393-1,254 (-0.60%)0.68%$1 MNov 10, 2026
13Janus Henderson Group Ltd.206,554—0.68%$1 MNov 16, 2026
14Privium Fund Management B.V.155,000+3,325 (+2.19%)0.51%$1 MNov 3, 2026
15CM Management, LLC120,000+60,000 (+100.00%)0.39%$1 MNov 12, 2026
16Northern Trust Corp104,985-713 (-0.67%)0.34%$1 MNov 16, 2026
17Vanguard Fiduciary Trust Co91,645-209 (-0.23%)0.30%$1 MNov 13, 2026
18Vanguard Portfolio Management LLC88,880+1,563 (+1.79%)0.29%$1 MNov 13, 2026
19Trexquant Investment LP74,615+33,569 (+81.78%)0.24%$1 MNov 16, 2026
20ADAR1 Capital Management, LLC73,877-25,000 (-25.28%)0.24%$1 MNov 16, 2026
21Renaissance Technologies LLC72,200+51,900 (+255.67%)0.24%$1 MNov 12, 2026
22Citadel Advisors LLC70,005New0.23%$1 MNov 16, 2026
23Nuveen, LLC69,193+5,739 (+9.04%)0.23%$0 MNov 10, 2026
24BNP Paribas Financial Markets65,754+1,777 (+2.78%)0.22%$0 MNov 12, 2026
25Acadian Asset Management LLC63,266+35,520 (+128.02%)0.21%$0 MNov 9, 2026

All 100 institutional investors: 26 to 100, with who bought and sold →

Mutual funds holding Cartesian Therapeutics, Inc.#

83 funds hold shares worth $24 M (about 7.3% of the company). Since their previous reports 42 added shares and 13 sold, buying $3 M net.
Mutual funds holding Cartesian Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.376,309$4 M1.2%<0.01%+34%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors338,605$4 M1.1%<0.01%+37%Jun 30, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC366,554$3 M1.2%0.05%no changeMay 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.169,730$2 M0.56%<0.01%+49%Jun 30, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC5.39 M$2 M—0.03%no changeMay 31, 2026
🇺🇸 Janus Henderson Small Cap Growth Alpha ETFJanus Henderson Investors US LLC195,163$2 M0.64%0.42%newJul 31, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC144,043$1 M0.47%<0.01%+39%Jul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors94,871$1 M0.31%<0.01%+9.1%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.265,512$1 M—<0.01%no changeJul 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors44,124$0 M0.14%0.03%+70%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC57,254$0 M0.19%<0.01%−3.3%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.53,464$0 M0.18%<0.01%+2.7%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC32,500$0 M0.11%0.23%+30%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.12 M$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC29,708$0 M0.10%<0.01%+69%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.32,118$0 M0.11%<0.01%+29%Jul 31, 2026
🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC22,160$0 M0.07%<0.01%newJun 30, 2026
🇺🇸 Clearwater Select Equity FundClearwater Management Co Inc.21,239$0 M0.07%0.04%+31%Jun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors17,053$0 M0.06%<0.01%+6.9%Jun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC16,271$0 M0.05%<0.01%+43%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC555,522$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.59,796$0 M—<0.01%no changeJul 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC17,320$0 M0.06%<0.01%+29%Jul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.12,395$0 M0.04%<0.01%+67%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC16,604$0 M0.05%<0.01%+10%May 31, 2026

As of Jul 31, 2026

Insider trading at Cartesian Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$206 K
1 purchase, 1 insider
Sold, 12 months
$259 K
3 sales, 3 insiders
Net, 12 months
-$53 K
open market only
Insiders on file
45
since
$7.4 M-$3.9 M$0Jan 2024: bought $0 (1 trades), sold $0 (0 trades)Jan 24Feb 2024: bought $0 (2 trades), sold $0 (0 trades)Mar 2024: bought $0 (10 trades), sold $0 (0 trades)MarAug 2024: bought $197 K (2 trades), sold $0 (0 trades)Oct 2024: bought $4.3 M (10 trades), sold $0 (0 trades)OctNov 2024: bought $7.4 M (5 trades), sold $3.9 M (14 trades)Dec 2024: bought $965 K (5 trades), sold $345 K (3 trades)DecJan 2025: bought $366 K (3 trades), sold $610 K (12 trades)Mar 2025: bought $1.4 M (3 trades), sold $0 (0 trades)MarApr 2025: bought $1.5 M (10 trades), sold $0 (0 trades)Dec 2025: bought $206 K (1 trades), sold $0 (0 trades)DecJan 2026: bought $0 (0 trades), sold $259 K (3 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Cartesian Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Elizabeth Hoge10% ownerOption exerciseindirect+758,001——5.31 MForm 4
filed Murat Kalayoglu10% ownerOption exerciseindirect+758,001——5.31 MForm 4
filed Michael SingerDirectorGift-6,555——49,578Form 4
filed Blaine DavisChief Financial OfficerSell-10,591$6.820$72 K121,220Form 4
filed Milos MiljkovicChief Medical OfficerSell-3,573$6.820$24 K58,820Form 4
filed Carsten BrunnPresident and CEO, DirectorSell-23,766$6.820$162 K323,530Form 4
filed Michael SingerDirectorGrant or award+2,600——56,133Form 4
filed Patrick J. ZennerDirectorGrant or award+2,600——12,974Form 4

Markets and events: Cartesian Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.9 M
7.4% of shares · 16.5 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-30.03 reverse split ; 3.9-for-1 split

Trading halts

  • 2026-06-09 13:35 UTC, code LUDP, resumed 13:40 UTC

Fails to deliver

  • : 1,641 shares at $6.28
  • : 8,768 shares at $6.08
  • : 945 shares at $6.27
  • : 1,732 shares at $6.68
  • : 1,289 shares at $7.36

Cartesian Therapeutics, Inc. scorecard#

Passes 2 of the 12 checks that could be worked out: strongest in financial health (2 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 27, 2026.

  • Valuation0 of 4
  • Growth0 of 2
  • Profitability0 of 2
  • Financial health2 of 3
  • Shareholder returns0 of 1

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Cartesian Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Cartesian Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue2.8392611185176.70.90.28.1
Research and development584571r72695543484530
General and administrative313040r24211916181913
Operating expenses1468311296907359666443
Operating income−143−44−8615−4.6−57−52−65−64−35
Interest and finance income6.67.45.0———————
Interest expense and finance costs—02.83.02.81.61.51.51.21.3
Other non-operating income (expense)3.9−33r0.70.30.00.1−1.30.0−0.20.0
Income before tax−139−77−23935−9.7−69−55———
Income tax−9.20.3−19−0.61600———
Net income attributable to shareholders−130−77−22035−26−69−55−65−65−36
Earnings per share, basic-5.02-4.48-49.76r0.24-0.22-0.68-1.22-2.92-3.20-3.89
Earnings per share, diluted-5.02-4.49-49.76r0.10-0.22-0.68-1.22-2.92-3.20-3.89
Shares, weighted average (basic)26175.2r14511410146———
Shares, weighted average (diluted)26175.2r14611410146222010
Balance sheet
Cash and cash equivalents12521377106114r13990377159
Short-term investments——028140—02625
Receivables1.10.95.96.69.97.25.000.10.2
Other current assets3.03.15.03.86.55.41.50.12.0r2.4
Current assets1292179114814415197429987
Property, plant and equipment129.92.12.82.11.41.22.12.12.0
Right-of-use (leased) assets5.65.510129.8110.3———
Goodwill4848480——————
Total assets2964353051661601651004410189
Accounts payable1.30.33.20.30.20.40.51.11.63.9
Current liabilities15236825728235351114
Long-term debt0—————————
Lease liabilities (non-current)8.5118.8108.69.60———
Total liabilities4234424457213718391504934
Retained earnings−822−692−615−395−430−405−336−280−217−152
Shareholders' equity−126−6.8−4409423−188.4−5.45255
Total liabilities and equity2964353051661601651004410189
Shares outstanding26265.4r15312410886222218
Cash-flow statement
Share-based compensation116.623117.75.45.25.74.12.1
Cash from operating activities−74−24−51−32−6035−51−59−52r−20r
Capital expenditure−5.5−9.1−0.2−1.2−1.1−0.8−0.0−0.9−0.7−0.6
Cash from investing activities−5.5−8.735−15−17−0.70.225−2.1−22
Debt issued———002500——
Debt repaid—0−2700−19−2.80−130
Shares issued———2.1522.1310102.7
Cash from financing activities−8.1168−133953141050.76668
Exchange-rate effect on cash0.0−0.0−0.10.0−0.0−0.10.0−0.20.10.5
Change in cash−87136−30−7.4−254954−3312r26r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Sep 30, 2026

What Cartesian Therapeutics, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Operating$3 M100%

As of Dec 31, 2025

Where Cartesian Therapeutics, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.

Cartesian Therapeutics, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office1 subsidiary—
🇷🇺 Russia1 subsidiary—

Executive pay at Cartesian Therapeutics, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$4.3 M
Dr. Brunn
Other top executives, average
$2.0 M
the CEO earned 2.1× this
$100 invested is now
$25
Cartesian Therapeutics, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Brunn$4.3 M−$634 K$2.0 M$25
2024Dr. Brunn$7.3 M$6.5 M$2.8 M$61
2023Dr. Brunn$6.1 M$6.4 M$1.8 M$70

As of Dec 31, 2025

Events at Cartesian Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 7 · Material agreement 1 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 9

Cartesian Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Shareholder vote8-K
Directors and officersMaterial agreementNew debtUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officersBylaws or fiscal year changed8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Results announced8-K

As of Nov 5, 2026

Acquisitions and funding#

1 acquisitions, $169 M paid where reported · 8 private funding rounds before listing

Businesses it acquired

Acquisitions by Cartesian Therapeutics, Inc.
AcquiredAcquisition dateCompletionPriceStakeSource
Old Cartesian2023—$169 M100%Annual report

Private share sales · funding history

Private share sales of Cartesian Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2024$130 MPrivate placement after listing$50 to $250 million22equitySEC
Jul 2020$25 MPrivate placement after listing$10 to $50 million1equitySEC
Dec 2019$70 MPrivate placement after listing$50 to $250 million26equity, optionsSEC
Aug 2019$6 MPrivate placement after listing$2 to $10 million10equitySEC
Jun 2017$50 MPrivate placement after listing$50 to $250 million11equity, optionsSEC
Dec 2016$5 MNo. 8$2 to $10 million1equitySEC
Aug 2015$37 MNo. 7$10 to $50 million19equity, optionsSEC
Apr 2015$6 MNo. 6$2 to $10 million12debt, optionsSEC
Aug 2014$4 MNo. 5$2 to $10 million11equitySEC
Jul 2014$6 MNo. 4$2 to $10 million2equitySEC
Apr 2014$5 MNo. 3$2 to $10 million11equitySEC
Nov 2011$22 MNo. 2$10 to $50 million16equitySEC
Mar 2010$15 MNo. 1$10 to $50 million14equitySEC

H-1B hiring at Cartesian Therapeutics, Inc.#

1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $73 K a year.

Certified, FY2024
1
#1,940 among companies on value.today
Worker positions
1
Median wage offered
$73 K
a year, full-time
Applications filed
1
Cartesian Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2024
Job titlePositionsMedian wage offered
Quality Control SpecialistMolecular and Cellular Biologists1$73 K

Where: Gaithersburg, MD 1

Layoffs at Cartesian Therapeutics, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2019–2019
Latest
—
2019-01-03
Cartesian Therapeutics, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2019············—
Cartesian Therapeutics, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
36% of workforceRestructuring planSEC 8-K“(“Selecta” or the “Company”) approved a plan to reduce Selecta’s headcount by approximately 36% (the “Workforce Reduction”) following a strategic review of the Company’s business.”Filing

How Cartesian Therapeutics, Inc. compares in Biotechnology

  • Market cap$192 M · higher than 44% of 732
  • Revenue growth49.6% · higher than 72% of 441
  • FCF yield-41.4% · higher than 27% of 456

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Cartesian Therapeutics, Inc.🇺🇸$192 M——+49.6%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Oct 27, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 22, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Cartesian Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Cartesian Therapeutics, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Cartesian Therapeutics, Inc.? Suggest a correction